FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental NDA (NDA 202570) for XALKORI (crizotinib) from Pfizer Laboratories Div Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Xalkori (crizotinib)

Snippet

SUPPL AP for XALKORI (CRIZOTINIB)